Ara
Toplam kayıt 4, listelenen: 1-4
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ...
Methodology of a new inflammatory arthritis registry: TReasure
(Tubitak Scientific & Technical Research Council Turkey, 2018)
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry ...
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(Wiley, 2018)
[No Abstract Available]
Biosimilar Infliximab Experience in Spondyloartritis Patients: Treasure Real Life Results
(Bmj Publishing Group, 2020)
[No Abstract Available]